A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) who have not experienced disease progression or unacceptable toxicity during chemotherapy.
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SATURN
- Sponsors Roche
- 07 Jan 2016 Results of pooled analysis of seven studies published in the Journal of Thoracic Oncology
- 01 Sep 2015 Post hoc analysis results from MERIT (n=102) and SATURN (n=262) studies published in the Journal of Thoracic Oncology.
- 10 Nov 2012 Planned number of patients changed from 850 to 864.